Use of autologous serum eyedrops for the treatment of ocular surface disease: first US experience in a large population as an insurance-covered benefit
Arch Ophthalmol
.
2012 Dec;130(12):1612-3.
doi: 10.1001/archophthalmol.2012.1652.
Authors
Cyril A Dalmon
,
Naveen S Chandra
,
Bennie H Jeng
PMID:
23229708
DOI:
10.1001/archophthalmol.2012.1652
No abstract available
Publication types
Letter
MeSH terms
Aged
Blood Transfusion, Autologous*
Eye Diseases / blood
Eye Diseases / therapy*
Female
Humans
Insurance Benefits
Male
Ophthalmic Solutions*
Retrospective Studies
United States
Substances
Ophthalmic Solutions